**Core Concept**
The management of precocious puberty involves halting the premature activation of the hypothalamic-pituitary-gonadal axis, thereby preventing further advancement of sexual maturation. In girls, the goal is to suppress gonadotropin secretion and subsequently reduce estrogen levels.

**Why the Correct Answer is Right**
Leuprolide acetate, a GnRH agonist, is the preferred treatment for central precocious puberty (CPP) in girls. When administered initially, leuprolide stimulates the pituitary gland to release gonadotropins, leading to a temporary surge in estrogen production. However, with continued administration, the pituitary gland downregulates GnRH receptors, resulting in decreased gonadotropin secretion and subsequently lower estrogen levels. This leads to a halt in the progression of puberty.

**Why Each Wrong Option is Incorrect**
**Option A:** **Spironolactone** is an anti-androgen, primarily used in the treatment of conditions such as hirsutism or acne in women with polycystic ovary syndrome (PCOS). It would not be effective in managing precocious puberty in girls.
**Option B:** **Danazol** is a synthetic androgen, which would potentially exacerbate the symptoms of precocious puberty in girls by increasing estrogen levels.
**Option C:** **Progesterone** is a sex hormone involved in the menstrual cycle, but it is not a suitable treatment for precocious puberty in girls, as it would not address the underlying issue of premature gonadotropin secretion.

**Clinical Pearl / High-Yield Fact**
GnRH agonists like leuprolide acetate can be used to treat both central and peripheral precocious puberty. However, peripheral precocious puberty is typically managed with medications that directly inhibit the effects of sex hormones, such as spironolactone for androgen excess.

**Correct Answer:** C. Leuprolide acetate.